SureNano Buys GlucaPharm to Drive Next-Generation GLP-1 Drug Push

The latest announcement is out from SureNano Science Ltd ( (TSE:SURE) ).

SureNano Science Ltd. has completed the acquisition of GlucaPharm Inc., gaining control of GEP44, a patented, second-generation GLP peptide that has shown significant weight-loss and blood-glucose benefits in preclinical studies with fewer gastrointestinal side effects than first-generation drugs such as Ozempic and Mounjaro. The all-share deal, which includes locked-up stock and warrants, accelerates SureNano’s shift into a near-term pharmaceutical value creator and is supported by the appointment of veteran drug developer Dr. Nihar R. Pandey as director and chief scientific officer.

GlucaPharm’s program targets the rapidly expanding GLP market with a differentiated asset that may be deliverable via non-injectable routes such as oral, sublingual or nasal formulations, a feature management believes could broaden patient adoption and deepen market penetration. The company is working with an Australian contract research organization to advance an IND-enabling FDA study and a Phase I trial in Australia, with key regulatory and early clinical milestones expected over the next six to nine months, positioning SureNano to compete in one of the decade’s most lucrative pharmaceutical segments.

The most recent analyst rating on (TSE:SURE) stock is a Hold with a C$0.30 price target. To see the full list of analyst forecasts on SureNano Science Ltd stock, see the TSE:SURE Stock Forecast page.

Spark’s Take on TSE:SURE Stock

According to Spark, TipRanks’ AI Analyst, TSE:SURE is a Neutral.

The score is primarily held down by very weak financial performance (zero recent revenue, ongoing losses and cash burn, and negative equity). Technicals provide partial support due to a strong uptrend, but overbought signals raise near-term risk. Recent financing improves liquidity somewhat, while valuation remains unattractive due to continued losses and no dividend.

To see Spark’s full report on TSE:SURE stock, click here.

More about SureNano Science Ltd

SureNano Science Ltd. is a Vancouver-based enabling-technology company transitioning into a pharmaceutical developer focused on advanced therapeutics delivery. Through the acquisition of GlucaPharm Inc., it is entering the fast-growing glucagon-like peptide drug market targeting obesity and metabolic disease with next-generation, better-tolerated treatments.

Average Trading Volume: 50,471

Technical Sentiment Signal: Buy

Current Market Cap: C$7.17M

Find detailed analytics on SURE stock on TipRanks’ Stock Analysis page.